Therapy-related MDS and AML in acute promyelocytic leukemia

Mette Klarskov Andersen and Jens Pedersen-Bjergaard

Article Figures & Data


  • Fig. 1-1.

    Clonality analysis of leukemic cells obtained from the initial APL phase (lane 1) and subsequently developed AML phase (lane 2) in patient 2.1-1

    RNA was reverse transcribed using random primers and cDNA were amplified with primers specific for the iduronate-2-sulfatase(IDS) gene as described.1-2 Amplified fragments were digested with the methylation-sensitive HpaII restriction endonuclease prior to agarose gel electrophoresis. Two differently sized bands of 133 and 158 bp are visible in lanes 1 and 2, which correspond to distinct allelic methylation patterns. M indicates molecular weight marker (ΦX 174 DNA/BsuRI).


  • Table 1.

    Type of chromosome aberration and type of previously administered chemotherapy in 49 consecutive cases of t-MDS and t-AML from the Copenhagen series3

    Alkylating agents without topoisomerase II inhibitorsTopoisomerase II inhibitors + alkylating agents or cisplatinSignificance by χ2 test
    Deletion or loss of 5q or 7q, monosomy 5 or monosomy 720/2412/25.02
    Balanced translocations to chromosome band 11q23 or 21q220/2412/25.0001